Shankar Siva on radiotherapy for primary renal cell carcinoma

The Lancet Oncology in conversation with - A podcast by The Lancet Group

Categories:

Education

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma. Read the full article: 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagr...